Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

References

• Lamb CA, Kennedy NA, Raine T, IBD guidelines eDelphi consensus group, et al. British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Lin S, Goodhand JR, Contributors to the CLARITY IBD study, et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–1893.
   PubMed Web of Science ®Google Scholar
• Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun Rev. 2022;21(1):102927.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Weaver KN, Boccieri M, PREVENT-COVID Study Group, et al. Humoral immune response to messenger RNA COVID-19 vaccines Among patients With inflammatory bowel disease. Gastroenterology. 2021;161(4):1340–1343.e2.
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Luna A, Micic D. Serologic response to coronavirus disease 2019 (COVID-19) vaccination in patients With Immune-Mediated inflammatory diseases: a systematic review and meta-analysis. Gastroenterology. 2022;162(1):88–108. e9.
   PubMed Web of Science ®Google Scholar
• Alexander JL, Kennedy NA, Ibraheim H, et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepat. 2022;7(4):342–352.
   PubMed Web of Science ®Google Scholar
• Syversen SW, Jyssum I, Tveter AT, et al. Immunogenicity and safety of standard and Third-Dose SARS-CoV-2 vaccination in patients receiving immunosuppressive therapy. Arthritis Rheumatol. 2022;74(8):1321–1332.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Principi M, Facciotti F, et al. Reduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: data from ESCAPE-IBD, an IG-IBD study. Dig Liver Dis. 2022;55(2):154–159.
   PubMedGoogle Scholar
• Shiga H, Kakuta Y, Abe AK, et al. Response to COVID-19 vaccine is reduced in patients with inflammatory bowel disease, but improved with additional dose. J Gastroenterol Hepatol. 2022;38(1):44–51.
   PubMed Web of Science ®Google Scholar
• Alexander JL, Moran GW, Gaya DR, Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group, et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a british society of gastroenterology inflammatory bowel disease section and IBD clinical research group position statement. Lancet Gastroenterol Hepatol. 2021;6(3):218–224.
   PubMed Web of Science ®Google Scholar
• Lin S, Lau LH, Chanchlani N, et al. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2022;71(7):1426–1439.
   PubMed Web of Science ®Google Scholar
• Cerna K, Duricova D, Lukas M, et al. Anti-SARS-CoV-2 vaccination and antibody response in patients With inflammatory bowel disease on immune-modifying therapy: prospective Single-Tertiary study. Inflamm Bowel Dis. 2021;28(10):1506–1512.
   Web of Science ®Google Scholar
• Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis. 2021;16(3):389–397.
   Web of Science ®Google Scholar
• Christensen IE, Jyssum I, Tveter AT, et al. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. BMC Med. 2022;20(1):378.
   PubMed Web of Science ®Google Scholar
• Norwegian Institute of Public Health. Norwegian Immunisation Registry (SYSVAK). https://www.fhi.no/en/hn/health-registries/norwegian-immunisation-registry-sysvak/
   Google Scholar
• Tran TT, Vaage EB, Mehta A, et al. Multiplexed measurement of binding- and neutralizing antibodies to SARS-CoV-2 variants in 12.000 post-vaccine sera. bioRxiv. 2022.
   Google Scholar
• Klaasen RA, Egeland EJ, Chan J, et al. A fully automated method for the determination of serum belatacept and its application in a pharmacokinetic investigation in renal transplant recipients. Ther Drug Monit. 2019;41(1):11–18.
   PubMed Web of Science ®Google Scholar
• Edelman-Klapper H, Zittan E, Bar GIL, REsponses to COVid-19 vaccinE IsRaeli IBD group (RECOVER), et al. Lower serologic response to COVID-19 mRNA vaccine in patients With inflammatory bowel diseases treated With Anti-TNFalpha. Gastroenterology. 2022;162(2):454–467.
   PubMed Web of Science ®Google Scholar
• Brkic A, Diamantopoulos AP, Haavardsholm EA, et al. Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs. BMC Health Serv Res. 2022;22(1):48.
   PubMed Web of Science ®Google Scholar
• Anisdahl K, Svatun Lirhus S, Medhus AW, et al. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a norwegian nationwide registry study. Scand J Gastroenterol. 2021;56(10):1163–1168.
   PubMed Web of Science ®Google Scholar
• Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383(27):2652–2664.
   PubMed Web of Science ®Google Scholar
• Wellens J, Edmans M, Obolski U, et al. Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease. Gut. 2021;71(9):1919–1922.
   PubMed Web of Science ®Google Scholar
• Muller KE, Dohos D, Sipos Z, et al. Immune response to influenza and pneumococcal vaccines in adults with inflammatory bowel disease: a systematic review and meta-analysis of 1429 patients. Vaccine. 2022;40(13):2076–2086.
   PubMed Web of Science ®Google Scholar
• Melmed GY, Botwin Gj Sobhani K, Li D, et al. Antibody responses After SARS-CoV-2 mRNA vaccination in adults With inflammatory bowel disease. Ann Intern Med. 2021;174(12):1768–1770.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, GEMINI 1 Study Group, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Manser CN, Maillard MH, Rogler G, et al. Vaccination in patients with inflammatory bowel diseases. Digestion. 2020;101(Suppl 1):58–68.
   PubMed Web of Science ®Google Scholar
• Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes. 2012;36(8):1072–1077.
   PubMed Web of Science ®Google Scholar
• Neidich SD, Green WD, Rebeles J, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes. 2017;41(9):1324–1330.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Balena A, Tuccinardi D, et al. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465.
   PubMed Web of Science ®Google Scholar
• Steensels D, Pierlet N, Penders J, et al. Comparison of SARS-CoV-2 antibody response Following vaccination With BNT162b2 and mRNA-1273. JAMA. 2021;326(15):1533–1535.
   PubMed Web of Science ®Google Scholar
• Caldera F, Knutson KL, Saha S, et al. Humoral immunogenicity of mRNA COVID-19 vaccines Among patients With inflammatory bowel disease and healthy controls. Am J Gastroenterol. 2022;117(1):176–179.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33:577–599.
   PubMed Web of Science ®Google Scholar
• Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9–15.
   PubMed Web of Science ®Google Scholar
• Pellini R, Venuti A, Pimpinelli F, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine. 2021;36:100928.
   PubMedGoogle Scholar
• Campos LM, Silva CA, Aikawa NE, et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res. 2013;65(7):1121–1127.
   PubMed Web of Science ®Google Scholar
• Velikova T, Georgiev T. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis. Rheumatol Int. 2021;41(3):509–518.
   PubMed Web of Science ®Google Scholar
• Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3.
   PubMed Web of Science ®Google Scholar